Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572152 | 0.89 | PPARA (0.59) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL3159484 | 0.89 | PPARA (0.59) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL13140901 | 0.88 | CYSLTR2 (0.55) | PPARAPPARGCYP4F2CYP4A11CYSLTR2 | |
| SCHEMBL2137203 | 0.87 | MAPK1 (0.66) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL3179476 | 0.84 | PPARA (0.55) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL8279857 | 0.84 | CYSLTR2 (0.54) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL3175607 | 0.84 | CYP4F2 (0.65) | PPARAPPARGCYP4F2CYP4A11TDP1 | |
| Hydrochloric Acid SCHEMBL688914 | 0.83 | CYSLTR2 (0.53) | PPARAPPARGCYSLTR2CYSLTR1MAPK1 | |
| SCHEMBL9168060 | 0.83 | PPARA (0.61) | PPARAPPARGCYP4F2CYP4A11MAPK1 | |
| SCHEMBL9170539 | 0.82 | PPARA (0.57) | PPARAPPARGCYP4F2CYP4A11CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102442941-A | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008072784-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PPARA 1122/4885PPARG 1069/4885CYP4F2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.